Cargando…
123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed...
Autores principales: | Raderer, M., Kurtaran, A., Hejna, M., Vorbeck, F., Angelberger, P., Scheithauer, W., Virgolini, I. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062941/ https://www.ncbi.nlm.nih.gov/pubmed/9662242 |
Ejemplares similares
-
Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results
por: Raderer, M, et al.
Publicado: (1999) -
Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011) -
Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type
por: Raderer, M, et al.
Publicado: (2001) -
Role of vasoactive intestinal peptide in osteoarthritis
por: Jiang, Wei, et al.
Publicado: (2016) -
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
por: Hejna, M., et al.
Publicado: (1998)